Skip to content
value.today

Baumer: peers

Change the peers

Baumer beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Baumer, Seyitler Kimya Sanayi A.S., TTBIO Corp.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Baumer, Retractable Technologies, Inc., Milestone Scientific Inc., Femasys Inc., Nephros, Inc., Harvard Bioscience, Inc., Seyitler Kimya Sanayi A.S., TTBIO Corp. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureBaumerbase
BALM4.SA · 🇧🇷 BR
Percentile in Healthcare
Percentile in Brazil
Retractable Technologies, Inc.
RVP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Milestone Scientific Inc.
MLSS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Femasys Inc.
FEMY · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nephros, Inc.
NEPH · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Harvard Bioscience, Inc.
HBIO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Seyitler Kimya Sanayi A.S.
SEYKM.IS · 🇹🇷 TR
Percentile in Healthcare
Percentile in Turkey
TTBIO Corp.
6493.TWO · 🇹🇼 TW
Percentile in Healthcare
Percentile in Taiwan
Group median
Size
Market cap (Better neither way: ranked highest first)$20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8$18 MOct 28, 2026 · Market data7th of 8$31 MOct 14, 2026 · Market data3rd of 8$12 MOct 29, 2026 · Market data8th of 8$36 MOct 30, 2026 · Market data2nd of 8$38 MOct 26, 2026 · Market data1st of 8$20 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8$20 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one4th of 8$20 M8 ranked
Revenue (Better neither way: ranked highest first)——$38 MFY2025 · SEC2nd of 5$9 MFY2025 · SEC4th of 5$2 MFY2025 · SEC5th of 5$19 MFY2025 · SEC3rd of 5$87 MFY2025 · SEC1st of 5————$19 M5 ranked
Net income (Higher is better)——$-13 MFY2025 · SEC3rd of 5$-6 MFY2025 · SEC2nd of 5$-19 MFY2025 · SEC4th of 5$1 MFY2025 · SEC1st of 5$-57 MFY2025 · SEC5th of 5————$-13 M5 ranked
Employees (Better neither way: ranked highest first)——201March 9, 2026 · Profile1st of 415December 31, 2025 · Profile4th of 451December 31, 2025 · Profile2nd of 436December 31, 2025 · Profile3rd of 4——————444 ranked
Growth
Revenue growth (Higher is better)————+15.8%FY2025 · SEC3rd of 560th73rd+3.9%FY2025 · SEC4th of 534th42nd+40.5%FY2025 · SEC1st of 582nd90th+32.7%FY2025 · SEC2nd of 578th87th-8.1%FY2025 · SEC5th of 515th13th————————+15.8%5 ranked
Revenue growth, 3 years a year (Higher is better)————-26.1%FY2025 · SEC5th of 56th2nd+0.6%FY2025 · SEC3rd of 529th35th+23.7%FY2025 · SEC1st of 576th88th+23.5%FY2025 · SEC2nd of 576th88th-8.6%FY2025 · SEC4th of 514th12th————————+0.6%5 ranked
Earnings per share growth (Higher is better)————————————————+1000.0%FY2025 · SEConly one with it100th100th————————————+1000.0%—
Margins and returns
Gross margin (Higher is better)————0.1%FY2025 · SEC5th of 52nd2nd71.5%FY2025 · SEC1st of 570th84th62.0%FY2025 · SEC2nd of 555th76th61.8%FY2025 · SEC3rd of 555th76th57.7%FY2025 · SEC4th of 549th72nd————————61.8%5 ranked
Operating margin (Higher is better)————-55.3%FY2025 · SEC2nd of 530th14th-63.5%FY2025 · SEC4th of 528th13th-768.1%FY2025 · SEC5th of 52nd1st6.1%FY2025 · SEC1st of 567th59th-56.1%FY2025 · SEC3rd of 530th14th————————-56.1%5 ranked
Net margin (Higher is better)————-32.9%FY2025 · SEC2nd of 536th17th-63.8%FY2025 · SEC3rd of 528th13th-813.5%FY2025 · SEC5th of 52nd1st6.3%FY2025 · SEC1st of 572nd65th-65.5%FY2025 · SEC4th of 528th12th————————-63.8%5 ranked
Free cash flow margin (Higher is better)————————-32.8%FY2025 · SEC2nd of 332nd14th-839.3%FY2025 · SEC3rd of 32nd1st————6.3%FY2025 · SEC1st of 365th59th————————-32.8%3 ranked
Return on equity (Higher is better)————-15.6%FY2025 · SEC2nd of 563rd30th-132.4%FY2025 · SEC3rd of 518th8th-456.1%FY2025 · SEC5th of 52nd1st12.7%FY2025 · SEC1st of 585th73rd-147.1%FY2025 · SEC4th of 516th7th————————-132.4%5 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————————————————18.7×price Oct 30, 2026 · Market dataonly one with it29th49th————————————18.7×—
Price to sales (Better neither way: ranked highest first)————0.5×price Oct 28, 2026 · Market data4th of 58th16th3.3×price Oct 14, 2026 · Market data2nd of 546th64th5.3×price Oct 29, 2026 · Market data1st of 558th79th1.6×price Oct 30, 2026 · Market data3rd of 528th43rd0.4×price Oct 26, 2026 · Market data5th of 57th13th————————1.6×5 ranked
Price to book (Better neither way: ranked highest first)————0.2×price Oct 28, 2026 · Market data5th of 52nd2nd11.0×price Oct 14, 2026 · Market data1st of 585th90th2.1×price Oct 29, 2026 · Market data4th of 539th49th3.5×price Oct 30, 2026 · Market data2nd of 555th67th2.7×price Oct 26, 2026 · Market data3rd of 546th59th————————2.7×5 ranked
Free cash flow yield (Higher is better)————-73.6%price Oct 28, 2026 · Market data4th of 511th4th-9.5%price Oct 14, 2026 · Market data3rd of 543rd21st-157.4%price Oct 29, 2026 · Market data5th of 53rd1st-1.6%price Oct 30, 2026 · Market data2nd of 563rd33rd14.5%price Oct 26, 2026 · Market data1st of 597th93rd————————-9.5%5 ranked
Financial strength
Debt to equity (Lower is better)————0.0×FY2025 · SEC1st of 210th7th————————————2.6×FY2025 · SEC2nd of 291st89th————————1.3×2 ranked
Interest cover (Higher is better)————————————————————-37.4×FY2025 · SEConly one with it25th11th————————-37.4×—
Piotroski F-score (Higher is better)——4 of 9FY2025 · SEC2nd of 2——————5 of 9FY2025 · SEC1st of 2————4.5 of 92 ranked
Scorecard
Scorecard (Higher is better)——7 of 22FY2025 · Scorecard3rd of 54 of 20FY2025 · Scorecard5th of 57 of 20FY2025 · Scorecard2nd of 512 of 21FY2025 · Scorecard1st of 56 of 23FY2025 · Scorecard4th of 5————32% passed5 ranked
Valuation checks (Higher is better)——2 of 5FY2025 · Scorecard3rd of 50 of 5FY2025 · Scorecard5th of 51 of 5FY2025 · Scorecard4th of 54 of 6FY2025 · Scorecard1st of 53 of 6FY2025 · Scorecard2nd of 5————40% passed5 ranked
Growth checks (Higher is better)——1 of 6FY2025 · Scorecard4th of 52 of 6FY2025 · Scorecard3rd of 54 of 6FY2025 · Scorecard2nd of 55 of 6FY2025 · Scorecard1st of 50 of 6FY2025 · Scorecard5th of 5————33% passed5 ranked
Profitability checks (Higher is better)——0 of 5FY2025 · Scorecard4th of 51 of 5FY2025 · Scorecard2nd of 51 of 5FY2025 · Scorecard2nd of 52 of 5FY2025 · Scorecard1st of 50 of 5FY2025 · Scorecard4th of 5————20% passed5 ranked
Financial health checks (Higher is better)——3 of 5FY2025 · Scorecard1st of 51 of 3FY2025 · Scorecard3rd of 51 of 3FY2025 · Scorecard3rd of 51 of 3FY2025 · Scorecard3rd of 52 of 5FY2025 · Scorecard2nd of 5————33% passed5 ranked
Shareholder returns checks (Higher is better)——1 of 1FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard3rd of 50 of 1FY2025 · Scorecard3rd of 50 of 1FY2025 · Scorecard3rd of 51 of 1FY2025 · Scorecard1st of 5————0% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——8.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 55.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 578.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 523.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 530.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5————23.7%5 ranked
Institutions holding (Better neither way: ranked highest first)——332026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 5322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 5272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 5362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 5————325 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——+0.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 4-0.3 pp2026-Q2 against 2026-Q1 · 13F3rd of 4——-1.5 pp2026-Q2 against 2026-Q1 · 13F4th of 4+26.7 pp2026-Q2 against 2026-Q1 · 13F1st of 4————+0.1 pp4 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Baumer: How market caps are worked out; Retractable Technologies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Milestone Scientific Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Femasys Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nephros, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Harvard Bioscience, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Seyitler Kimya Sanayi A.S.: How market caps are worked out; TTBIO Corp.: Taiwan Stock Exchange and Taipei Exchange, issued shares times the close.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Baumer———
Retractable Technologies, Inc.-55.3%FY2025
30th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies
Milestone Scientific Inc.-63.5%FY2025
28th percentile in Healthcaremedian -7.7%, 674 companies
13th percentile in USAmedian 3.5%, 2,594 companies
Femasys Inc.-768.1%FY2025
2nd percentile in Healthcaremedian -7.7%, 674 companies
1st percentile in USAmedian 3.5%, 2,594 companies
Nephros, Inc.6.1%FY2025
67th percentile in Healthcaremedian -7.7%, 674 companies
59th percentile in USAmedian 3.5%, 2,594 companies
Harvard Bioscience, Inc.-56.1%FY2025
30th percentile in Healthcaremedian -7.7%, 674 companies
14th percentile in USAmedian 3.5%, 2,594 companies
Seyitler Kimya Sanayi A.S.———
TTBIO Corp.———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$47 M$94 M$141 M$188 M20102012201420162018202020222024Retractable Technologies, Inc. $38 MMilestone Scientific Inc. $9 MFemasys Inc. $2 MNephros, Inc. $19 MHarvard Bioscience, Inc. $87 M

Rank in the group

1st2nd3rd4th5th201120122013201420152016201720182019202020212022202320242025Retractable Technologies, Inc.: 2nd of 4 in 2011Retractable Technologies, Inc.: 2nd of 4 in 2012Retractable Technologies, Inc.: 2nd of 4 in 2013Retractable Technologies, Inc.: 2nd of 4 in 2014Retractable Technologies, Inc.: 2nd of 4 in 2015Retractable Technologies, Inc.: 2nd of 4 in 2016Retractable Technologies, Inc.: 2nd of 4 in 2017Retractable Technologies, Inc.: 2nd of 4 in 2018Retractable Technologies, Inc.: 2nd of 4 in 2019Retractable Technologies, Inc.: 2nd of 5 in 2020Retractable Technologies, Inc.: 1st of 5 in 2021Retractable Technologies, Inc.: 2nd of 5 in 2022Retractable Technologies, Inc.: 2nd of 5 in 2023Retractable Technologies, Inc.: 2nd of 5 in 2024Retractable Technologies, Inc.: 2nd of 5 in 2025Retractable Technologies, Milestone Scientific Inc.: 3rd of 4 in 2011Milestone Scientific Inc.: 3rd of 4 in 2012Milestone Scientific Inc.: 3rd of 4 in 2013Milestone Scientific Inc.: 3rd of 4 in 2014Milestone Scientific Inc.: 3rd of 4 in 2015Milestone Scientific Inc.: 3rd of 4 in 2016Milestone Scientific Inc.: 3rd of 4 in 2017Milestone Scientific Inc.: 3rd of 4 in 2018Milestone Scientific Inc.: 4th of 4 in 2019Milestone Scientific Inc.: 4th of 5 in 2020Milestone Scientific Inc.: 3rd of 5 in 2021Milestone Scientific Inc.: 4th of 5 in 2022Milestone Scientific Inc.: 4th of 5 in 2023Milestone Scientific Inc.: 4th of 5 in 2024Milestone Scientific Inc.: 4th of 5 in 2025Milestone Scientific Inc.Femasys Inc.: 5th of 5 in 2020Femasys Inc.: 5th of 5 in 2021Femasys Inc.: 5th of 5 in 2022Femasys Inc.: 5th of 5 in 2023Femasys Inc.: 5th of 5 in 2024Femasys Inc.: 5th of 5 in 2025Femasys Inc.Nephros, Inc.: 4th of 4 in 2011Nephros, Inc.: 4th of 4 in 2012Nephros, Inc.: 4th of 4 in 2013Nephros, Inc.: 4th of 4 in 2014Nephros, Inc.: 4th of 4 in 2015Nephros, Inc.: 4th of 4 in 2016Nephros, Inc.: 4th of 4 in 2017Nephros, Inc.: 4th of 4 in 2018Nephros, Inc.: 3rd of 4 in 2019Nephros, Inc.: 3rd of 5 in 2020Nephros, Inc.: 4th of 5 in 2021Nephros, Inc.: 3rd of 5 in 2022Nephros, Inc.: 3rd of 5 in 2023Nephros, Inc.: 3rd of 5 in 2024Nephros, Inc.: 3rd of 5 in 2025Nephros, Inc.Harvard Bioscience, Inc.: 1st of 4 in 2011Harvard Bioscience, Inc.: 1st of 4 in 2012Harvard Bioscience, Inc.: 1st of 4 in 2013Harvard Bioscience, Inc.: 1st of 4 in 2014Harvard Bioscience, Inc.: 1st of 4 in 2015Harvard Bioscience, Inc.: 1st of 4 in 2016Harvard Bioscience, Inc.: 1st of 4 in 2017Harvard Bioscience, Inc.: 1st of 4 in 2018Harvard Bioscience, Inc.: 1st of 4 in 2019Harvard Bioscience, Inc.: 1st of 5 in 2020Harvard Bioscience, Inc.: 2nd of 5 in 2021Harvard Bioscience, Inc.: 1st of 5 in 2022Harvard Bioscience, Inc.: 1st of 5 in 2023Harvard Bioscience, Inc.: 1st of 5 in 2024Harvard Bioscience, Inc.: 1st of 5 in 2025Harvard Bioscience, Inc.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearBaumerRetractable Technologies, Inc.Milestone Scientific Inc.Femasys Inc.Nephros, Inc.Harvard Bioscience, Inc.Seyitler Kimya Sanayi A.S.TTBIO Corp.
2025—$38 MSEC2nd$9 MSEC4th$2 MSEC5th$19 MSEC3rd$87 MSEC1st——
2024—$33 MSEC2nd$9 MSEC4th$2 MSEC5th$14 MSEC3rd$94 MSEC1st——
2023—$44 MSEC2nd$10 MSEC4th$1 MSEC5th$14 MSEC3rd$112 MSEC1st——
2022—$95 MSEC2nd$9 MSEC4th$1 MSEC5th$10 MSEC3rd$113 MSEC1st——
2021—$188 MSEC1st$10 MSEC3rd$1 MSEC5th$10 MSEC4th$119 MSEC2nd——
2020—$82 MSEC2nd$5 MSEC4th$1 MSEC5th$9 MSEC3rd$102 MSEC1st——
2019—$42 MSEC2nd$8 MSEC4th—$10 MSEC3rd$116 MSEC1st——
2018—$33 MSEC2nd$10 MSEC3rd—$6 MSEC4th$121 MSEC1st——
2017—$34 MSEC2nd$11 MSEC3rd—$4 MSEC4th$77 MSEC1st——
2016—$30 MSEC2nd$10 MSEC3rd—$2 MSEC4th$105 MSEC1st——
2015—$30 MSEC2nd$9 MSEC3rd—$2 MSEC4th$109 MSEC1st——
2014—$35 MSEC2nd$10 MSEC3rd—$2 MSEC4th$109 MSEC1st——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Baumer#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Retractable Technologies, Inc.RVP · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $18 M market cap against $20 M · Ratios of the last two fiscal years on file
    Market cap $18 M (Oct 28, 2026) · revenue $38 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Milestone Scientific Inc.MLSS · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $31 M market cap against $20 M · Ratios of the last two fiscal years on file
    Market cap $31 M (Oct 14, 2026) · revenue $9 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    In the group
  • Femasys Inc.FEMY · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $12 M market cap against $20 M · Ratios of the last two fiscal years on file
    Market cap $12 M (Oct 29, 2026) · revenue $2 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    In the group
  • Nephros, Inc.NEPH · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $36 M market cap against $20 M · Ratios of the last two fiscal years on file
    Market cap $36 M (Oct 30, 2026) · revenue $19 M (year to December 2025)
    81 of 100 (industry or sector 50 + size 26 + figures on file 5)
    In the group
  • Harvard Bioscience, Inc.HBIO · 🇺🇸 USA
    Same industry: Medical Instruments · Similar size: $38 M market cap against $20 M · Ratios of the last two fiscal years on file
    Market cap $38 M (Oct 26, 2026) · revenue $87 M (year to December 2025)
    81 of 100 (industry or sector 50 + size 26 + figures on file 5)
    In the group
  • Seyitler Kimya Sanayi A.S.SEYKM.IS · 🇹🇷 Turkey
    Same industry: Medical Instruments · Similar size: $20 M market cap against $20 M
    Market cap $20 M (last known, Jan 5, 2024)
    80 of 100 (industry or sector 50 + size 30)
    In the group
  • TTBIO Corp.6493.TWO · 🇹🇼 Taiwan
    Same industry: Medical Instruments · Similar size: $20 M market cap against $20 M
    Market cap $20 M (last known, Jul 30, 2023)
    80 of 100 (industry or sector 50 + size 30)
    In the group
  • Sona Nanotech Inc.SONA.CN · 🇨🇦 Canada
    Same industry: Medical Instruments · Similar size: $20 M market cap against $20 M
    Market cap $20 M (last known, Jan 5, 2024)
    80 of 100 (industry or sector 50 + size 30)
    + Add
  • Comfort Gloves Berhad2127.KL · 🇲🇾 Malaysia
    Same industry: Medical Instruments · Similar size: $21 M market cap against $20 M
    Market cap $21 M (Aug 1, 2026)
    80 of 100 (industry or sector 50 + size 30)
    + Add
  • Sincere Co., Ltd.7782.T · 🇯🇵 Japan
    Same industry: Medical Instruments · Similar size: $19 M market cap against $20 M
    Market cap $19 M (last known, Mar 8, 2026)
    80 of 100 (industry or sector 50 + size 30)
    + Add
  • Kaisa Health Group Holdings Limited0876.HK · 🇭🇰 Hong Kong
    Same industry: Medical Instruments · Similar size: $23 M market cap against $20 M
    Market cap $23 M (last known, Jan 5, 2024)
    79 of 100 (industry or sector 50 + size 29)
    + Add
  • Elegance Optical International Holdings Limited0907.HK · 🇭🇰 Hong Kong
    Same industry: Medical Instruments · Similar size: $17 M market cap against $20 M
    Market cap $17 M (last known, Jan 5, 2024)
    79 of 100 (industry or sector 50 + size 29)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.